Efficacy and tolerability of topiramate in children younger than 2 years old

Journal of Child Neurology

Volumn 20, Issue 8, 2005, Pages 667-670

  Valencia, Ignacio ^a   Fons, Carmen ^a   Kothare, Sanjeev V ^a   Khurana, Divya S ^a   Yum, Sabrina ^a   Hardison, H Huntley ^a   Legido, Agustin ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLONAZEPAM; ETIRACETAM; LAMOTRIGINE; TOPIRAMATE; VALPROIC ACID;

ANOREXIA; CLINICAL ARTICLE; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GRAND MAL SEIZURE; HUMAN; HYPERTHERMIA; INFANT; INFANTILE SPASM; INFORMATION RETRIEVAL; KETOGENIC DIET; LETHARGY; MALE; MONOTHERAPY; MYOCLONUS SEIZURE; ONSET AGE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGE FACTORS; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES;

EID: 30944447476     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738050200080601     Document Type: Review

References (28)

1. Mikaeloff Y, de Saint-Martin A, Mancini J, et al: Topiramate: Efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res 2003;53:225-232.
2. French JA, Kanner AM, Bautista J, et al: Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1261-1273.
3. Kothare SV, Khurana DS, Valencia I, et al: Efficacy and tolerability of topiramate as monotherapy in epilepsy: Pediatric experience. Ann Neurol 2004;56(Suppl 8):S116.
4. Herranz JL: Topiramate: A broad spectrum antiepileptic administered to 224 patients with refractory epilepsies. Rev Neurol (Spain) 2000;31:822-828.
5. Watemberg N, Goldberg-Stern H, Ben-Zeev B, et al: Clinical experience with open-label topiramate in infants younger than 2 years of age. J Child Neurol 2003;18:258-262.
6. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE: An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41(Suppl 1):S3-S9.
7. Sulzbacher S, Farwell JR, Temkin N, et al: Late cognitive effects of early treatment with phenobarbital. Clin Pediatr 1999; 38:387-394.
8. Coppola G, Caliendo G, Veggiotti P, et al: Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: An Italian multicentric study. Epilepsy Res 2002;51:147-153.
9. Glauser TA, Levisohn PM, Ritter F, Sachdeo RC: Topiramate in Lennox-Gastaut syndrome: Open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia 2000;41(Suppl 1):S86-S90.
10. Yeung S, Ferrie CD, Murdoch-Eaton DG, Livingston JH: Topiramate for drug-resistant epilepsies. Eur J Paediatr Neurol 2000; 4:31-3.
11. Guerreiro MM, Manreza ML, Scotoni AE, et al: A pilot study of topiramate in children with Lennox-Gastaut syndrome. Arq Neuropsiquiatr 1999;57:167-175.
12. Glauser TA, Clark PO, McGee K: Long-term response to topiramate in patients with West syndrome. Epilepsia 2000;41(Suppl 1):S91-S94.
13. Veggiotti P, Longaretti F, Signorini S, et al: Topiramate efficacy in an infant with partial seizures refractory to conventional antiepileptic drugs. Seizure 2004;13:241-243.
14. Kugler SL, Sachdeo RC: Topiramate efficacy in infancy. Pediatr Neurol 1998;19:320-322.
15. Glauser TA, Miles MV, Tang P, et al: Topiramate pharmacokinetics in infants. Epilepsia 1999;40:788-791.
16. French JA, Kanner AM, Bautista J, et al: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1252-1260.
17. Arcas J, Ferrer T, Roche MC, et al: Hypohidrosis related to the administration of topiramate to children. Epilepsia 2001;42: 1363-1365.
18. Lee S, Sziklas V, Andermann F, et al: The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 2003;44:339-347.
19. Thompson PJ, Baxendale SA, Duncan JS, Sander JW: Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000;69:636-641.
20. Gross-Tsur V, Shalev RS: Reversible language regression as an adverse effect of topiramate treatment in children. Neurology 2004;62:299-300.
21. Sie LTL, Rombouts SA, Valk IJ, et al: Functional MRI of visual cortex in sedated 18 month-old infants with or without periventricular leukomalacia. Dev Med Child Neurol 2001;43:486-490.
22. Yamada H, Sadato N, Konishi Y, et al: A milestone for normal development of the infantile brain detected by functional MRI. Neurology 2000;55:218-223.
23. Souweidane MM, Kim KH, McDowall R, et al: Brain mapping in sedated infants and young children with passive-functional magnetic resonance imaging. Pediatr Neurosurg 1999;30:86-92.
24. Muller RA, Behen ME, Rothermel RD, et al: Brain organization for language in children, adolescents, and adults with left hemisphere lesion: A PET study. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:657-668.
25. Chugani HT, Da Silva E, Chugani DC: Infantile spasms: III. Prognostic implications of bitemporal hypometabolism on positron emission tomography. Ann Neurol 1996;39:643-649.
26. Chugani HT: Positron emission tomography scanning: Applications in newborns. Clin Perinatol 1993;20:395-409.
27. Koh S, Jensen FE: Topiramate blocks perinatal hypoxia-induced seizures in rat pups. Ann Neurol 2001;50:366-372.
28. Valencia I, Legido A: Prevention of epilepsy, in Benjamin SM (ed): Focus on Epilepsy Research. Hauppauge, NY, Nova Science, 2004, 1-21.